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Background
In Brazil, the most prevalent cases of TTR-related amy-
loidoses is the V30M variant due the Portuguese coloni-
zation. Our group has stablished a center for molecular
diagnostic of FAP. Since then, we have sequenced almost
one hundred patients form the University Hospital and
their relatives. Recently, we identified a patient with a
severe cardiomyopathy. This patient has a German ances-
try and the sequence of his TTR gene revealed the pre-
sence of a new mutation, namely A19D. This patient
presented heart failure and was classified by the NIHA as
IV. We have also identified a patient, 66-years old, from a
family with African ancestry, which bears the typical
V122I mutation. This patient presented carpal tunnel
syndrome and two years later developed heart failure that
progressed to NYHA III. The main goal of the present
work is to characterize the Brazilian population with
FAC by combining bioinformatics and biophysical
studies.
Methods
We built a model for A19D by using FoldX (http://foldx.
crg.es/) with the original WT-TTR structure as deposited
in the PDB under code 1F41. The toxicity of amyloid
aggregates composed of A19D and V122I were evaluated
by using cell viability assay in primary culture of murine
cardiomyocytes and fibroblasts as well as N2a cell line.
Results: Initially we used the bioinformatics tool FoldX to
predict the thermodynamic stability of the new mutant
A19D. Our predictions have shown that the insertion of
mutation caused a decrease in the thermodynamic stability
of the protein and cause an electrostatic clash in the
region of thyroxine channel that could facilitate their dis-
sociation. A19D was purified heterologously and biophysi-
cal studies demonstrated that this mutant is a dimer and
not a tetramer as wild type structure. The crystallographic
structure of A19D is identical of wild type TTR. Thermo-
dynamic studies with A19D indicated that it has a lower
stability than the wild-type protein and other mutants.
This new mutant has a faster aggregation kinetics forming
amyloid fibers in two hours as shown by images. Amyloid
aggregates of A19D and V122I were incubated with pri-
mary culture of cardiomyocytes and fibroblasts from mur-
ine heart and also in N2a cell line. The viability assay
showed that the oligomers of A19D and V122I are toxic
for cardiomyocytes and neuroblastoma cells and interest-
ingly fibroblasts also suffer injury in the presence of these
aggregates.
Conclusions
The recent consolidation of TTR diagnosis in our Uni-
versity Hospital led to the identification of a rare, new
variant of TTR in Brazil, namely, A19D, as well as the
common V122I variant. A19D presented a marginal ther-
modynamic stability as inferred by bioinformatics and by
biophysical studies with the purified protein. A19D
showed to be dimer in solution. The viability assay shows
that toxic mechanism displayed by this new mutant can
be directly correlated with the aggressiveness observed in
the disease developed by the patient.
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